Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer
Vries, E. G. E. ; Rodenhuis, S. ; Schouten, H. C. ; Hupperets, P. S. G. J. ; Dolsma, W. V. ; Lebesque, J. V. ; Blijham, G. H. ; Bontenbal, M. ; Mulder, N. H.
Springer
Published 1996
Springer
Published 1996
| ISSN: |
1573-7217
|
|---|---|
| Keywords: |
high-dose chemotherapy ; metastatic breast cancer
|
| Source: |
Springer Online Journal Archives 1860-2000
|
| Topics: |
Medicine
|
| Notes: |
Summary Background This trial studied the disease-free survival after high-dose chemotherapy in patients in complete remission of metastatic breast cancer. Patients and methods Thirty women, mean age 42.2 years (range 33–55) with metastatic breast cancer, received high-dose chemotherapy in a phase II study. Patients were eligible if they were ≤ 55 years of age, had achieved complete remission within 6 months of the initiation of chemotherapy, and had a WHO performance scale of 0 or 1. The high-dose regimen consisted of melphalan 180 mg/m2 and mitoxantrone 60 mg/m2 both divided over 3 days. On day 7 bone marrow and/or peripheral stem cells were infused. After bone marrow recovery, external beam radiation was administered to sites of previous metastatic disease in 15 patients. Results Apart from leuko- and thrombocytopenia, mucositis was the major side effect. One patient died during the bone marrow transplant period due to an aspergillus infection. The median follow-up since highdose chemotherapy is 25 months (range 13 to 56 months). The median disease-free survival since high-dose chemotherapy is 27 months and the disease free survival is still 43% with an overall survival of 53% at 3 years. In two patients tumor relapse occurred only in the brain; in one patient the only relapse sign was a meningeal carcinosis. At the moment 17 patients are disease-free (13+–56+) months after high-dose chemotherapy. Conclusion Until now this high-dose regimen in selected patients with complete remission after induction chemotherapy for metastatic breast cancer has a promising disease free survival.
|
| Type of Medium: |
Electronic Resource
|
| URL: |
| _version_ | 1798296892462858242 |
|---|---|
| autor | Vries, E. G. E. Rodenhuis, S. Schouten, H. C. Hupperets, P. S. G. J. Dolsma, W. V. Lebesque, J. V. Blijham, G. H. Bontenbal, M. Mulder, N. H. |
| autorsonst | Vries, E. G. E. Rodenhuis, S. Schouten, H. C. Hupperets, P. S. G. J. Dolsma, W. V. Lebesque, J. V. Blijham, G. H. Bontenbal, M. Mulder, N. H. |
| book_url | http://dx.doi.org/10.1007/BF01806158 |
| datenlieferant | nat_lic_papers |
| hauptsatz | hsatz_simple |
| identnr | NLM196736021 |
| issn | 1573-7217 |
| journal_name | Breast cancer research and treatment |
| materialart | 1 |
| notes | Summary Background This trial studied the disease-free survival after high-dose chemotherapy in patients in complete remission of metastatic breast cancer. Patients and methods Thirty women, mean age 42.2 years (range 33–55) with metastatic breast cancer, received high-dose chemotherapy in a phase II study. Patients were eligible if they were ≤ 55 years of age, had achieved complete remission within 6 months of the initiation of chemotherapy, and had a WHO performance scale of 0 or 1. The high-dose regimen consisted of melphalan 180 mg/m2 and mitoxantrone 60 mg/m2 both divided over 3 days. On day 7 bone marrow and/or peripheral stem cells were infused. After bone marrow recovery, external beam radiation was administered to sites of previous metastatic disease in 15 patients. Results Apart from leuko- and thrombocytopenia, mucositis was the major side effect. One patient died during the bone marrow transplant period due to an aspergillus infection. The median follow-up since highdose chemotherapy is 25 months (range 13 to 56 months). The median disease-free survival since high-dose chemotherapy is 27 months and the disease free survival is still 43% with an overall survival of 53% at 3 years. In two patients tumor relapse occurred only in the brain; in one patient the only relapse sign was a meningeal carcinosis. At the moment 17 patients are disease-free (13+–56+) months after high-dose chemotherapy. Conclusion Until now this high-dose regimen in selected patients with complete remission after induction chemotherapy for metastatic breast cancer has a promising disease free survival. |
| package_name | Springer |
| publikationsjahr_anzeige | 1996 |
| publikationsjahr_facette | 1996 |
| publikationsjahr_intervall | 8004:1995-1999 |
| publikationsjahr_sort | 1996 |
| publisher | Springer |
| reference | 39 (1996), S. 307-313 |
| schlagwort | high-dose chemotherapy metastatic breast cancer |
| search_space | articles |
| shingle_author_1 | Vries, E. G. E. Rodenhuis, S. Schouten, H. C. Hupperets, P. S. G. J. Dolsma, W. V. Lebesque, J. V. Blijham, G. H. Bontenbal, M. Mulder, N. H. |
| shingle_author_2 | Vries, E. G. E. Rodenhuis, S. Schouten, H. C. Hupperets, P. S. G. J. Dolsma, W. V. Lebesque, J. V. Blijham, G. H. Bontenbal, M. Mulder, N. H. |
| shingle_author_3 | Vries, E. G. E. Rodenhuis, S. Schouten, H. C. Hupperets, P. S. G. J. Dolsma, W. V. Lebesque, J. V. Blijham, G. H. Bontenbal, M. Mulder, N. H. |
| shingle_author_4 | Vries, E. G. E. Rodenhuis, S. Schouten, H. C. Hupperets, P. S. G. J. Dolsma, W. V. Lebesque, J. V. Blijham, G. H. Bontenbal, M. Mulder, N. H. |
| shingle_catch_all_1 | Vries, E. G. E. Rodenhuis, S. Schouten, H. C. Hupperets, P. S. G. J. Dolsma, W. V. Lebesque, J. V. Blijham, G. H. Bontenbal, M. Mulder, N. H. Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer high-dose chemotherapy metastatic breast cancer high-dose chemotherapy metastatic breast cancer Summary Background This trial studied the disease-free survival after high-dose chemotherapy in patients in complete remission of metastatic breast cancer. Patients and methods Thirty women, mean age 42.2 years (range 33–55) with metastatic breast cancer, received high-dose chemotherapy in a phase II study. Patients were eligible if they were ≤ 55 years of age, had achieved complete remission within 6 months of the initiation of chemotherapy, and had a WHO performance scale of 0 or 1. The high-dose regimen consisted of melphalan 180 mg/m2 and mitoxantrone 60 mg/m2 both divided over 3 days. On day 7 bone marrow and/or peripheral stem cells were infused. After bone marrow recovery, external beam radiation was administered to sites of previous metastatic disease in 15 patients. Results Apart from leuko- and thrombocytopenia, mucositis was the major side effect. One patient died during the bone marrow transplant period due to an aspergillus infection. The median follow-up since highdose chemotherapy is 25 months (range 13 to 56 months). The median disease-free survival since high-dose chemotherapy is 27 months and the disease free survival is still 43% with an overall survival of 53% at 3 years. In two patients tumor relapse occurred only in the brain; in one patient the only relapse sign was a meningeal carcinosis. At the moment 17 patients are disease-free (13+–56+) months after high-dose chemotherapy. Conclusion Until now this high-dose regimen in selected patients with complete remission after induction chemotherapy for metastatic breast cancer has a promising disease free survival. 1573-7217 15737217 Springer |
| shingle_catch_all_2 | Vries, E. G. E. Rodenhuis, S. Schouten, H. C. Hupperets, P. S. G. J. Dolsma, W. V. Lebesque, J. V. Blijham, G. H. Bontenbal, M. Mulder, N. H. Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer high-dose chemotherapy metastatic breast cancer high-dose chemotherapy metastatic breast cancer Summary Background This trial studied the disease-free survival after high-dose chemotherapy in patients in complete remission of metastatic breast cancer. Patients and methods Thirty women, mean age 42.2 years (range 33–55) with metastatic breast cancer, received high-dose chemotherapy in a phase II study. Patients were eligible if they were ≤ 55 years of age, had achieved complete remission within 6 months of the initiation of chemotherapy, and had a WHO performance scale of 0 or 1. The high-dose regimen consisted of melphalan 180 mg/m2 and mitoxantrone 60 mg/m2 both divided over 3 days. On day 7 bone marrow and/or peripheral stem cells were infused. After bone marrow recovery, external beam radiation was administered to sites of previous metastatic disease in 15 patients. Results Apart from leuko- and thrombocytopenia, mucositis was the major side effect. One patient died during the bone marrow transplant period due to an aspergillus infection. The median follow-up since highdose chemotherapy is 25 months (range 13 to 56 months). The median disease-free survival since high-dose chemotherapy is 27 months and the disease free survival is still 43% with an overall survival of 53% at 3 years. In two patients tumor relapse occurred only in the brain; in one patient the only relapse sign was a meningeal carcinosis. At the moment 17 patients are disease-free (13+–56+) months after high-dose chemotherapy. Conclusion Until now this high-dose regimen in selected patients with complete remission after induction chemotherapy for metastatic breast cancer has a promising disease free survival. 1573-7217 15737217 Springer |
| shingle_catch_all_3 | Vries, E. G. E. Rodenhuis, S. Schouten, H. C. Hupperets, P. S. G. J. Dolsma, W. V. Lebesque, J. V. Blijham, G. H. Bontenbal, M. Mulder, N. H. Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer high-dose chemotherapy metastatic breast cancer high-dose chemotherapy metastatic breast cancer Summary Background This trial studied the disease-free survival after high-dose chemotherapy in patients in complete remission of metastatic breast cancer. Patients and methods Thirty women, mean age 42.2 years (range 33–55) with metastatic breast cancer, received high-dose chemotherapy in a phase II study. Patients were eligible if they were ≤ 55 years of age, had achieved complete remission within 6 months of the initiation of chemotherapy, and had a WHO performance scale of 0 or 1. The high-dose regimen consisted of melphalan 180 mg/m2 and mitoxantrone 60 mg/m2 both divided over 3 days. On day 7 bone marrow and/or peripheral stem cells were infused. After bone marrow recovery, external beam radiation was administered to sites of previous metastatic disease in 15 patients. Results Apart from leuko- and thrombocytopenia, mucositis was the major side effect. One patient died during the bone marrow transplant period due to an aspergillus infection. The median follow-up since highdose chemotherapy is 25 months (range 13 to 56 months). The median disease-free survival since high-dose chemotherapy is 27 months and the disease free survival is still 43% with an overall survival of 53% at 3 years. In two patients tumor relapse occurred only in the brain; in one patient the only relapse sign was a meningeal carcinosis. At the moment 17 patients are disease-free (13+–56+) months after high-dose chemotherapy. Conclusion Until now this high-dose regimen in selected patients with complete remission after induction chemotherapy for metastatic breast cancer has a promising disease free survival. 1573-7217 15737217 Springer |
| shingle_catch_all_4 | Vries, E. G. E. Rodenhuis, S. Schouten, H. C. Hupperets, P. S. G. J. Dolsma, W. V. Lebesque, J. V. Blijham, G. H. Bontenbal, M. Mulder, N. H. Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer high-dose chemotherapy metastatic breast cancer high-dose chemotherapy metastatic breast cancer Summary Background This trial studied the disease-free survival after high-dose chemotherapy in patients in complete remission of metastatic breast cancer. Patients and methods Thirty women, mean age 42.2 years (range 33–55) with metastatic breast cancer, received high-dose chemotherapy in a phase II study. Patients were eligible if they were ≤ 55 years of age, had achieved complete remission within 6 months of the initiation of chemotherapy, and had a WHO performance scale of 0 or 1. The high-dose regimen consisted of melphalan 180 mg/m2 and mitoxantrone 60 mg/m2 both divided over 3 days. On day 7 bone marrow and/or peripheral stem cells were infused. After bone marrow recovery, external beam radiation was administered to sites of previous metastatic disease in 15 patients. Results Apart from leuko- and thrombocytopenia, mucositis was the major side effect. One patient died during the bone marrow transplant period due to an aspergillus infection. The median follow-up since highdose chemotherapy is 25 months (range 13 to 56 months). The median disease-free survival since high-dose chemotherapy is 27 months and the disease free survival is still 43% with an overall survival of 53% at 3 years. In two patients tumor relapse occurred only in the brain; in one patient the only relapse sign was a meningeal carcinosis. At the moment 17 patients are disease-free (13+–56+) months after high-dose chemotherapy. Conclusion Until now this high-dose regimen in selected patients with complete remission after induction chemotherapy for metastatic breast cancer has a promising disease free survival. 1573-7217 15737217 Springer |
| shingle_title_1 | Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer |
| shingle_title_2 | Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer |
| shingle_title_3 | Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer |
| shingle_title_4 | Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer |
| sigel_instance_filter | dkfz geomar wilbert ipn albert fhp |
| source_archive | Springer Online Journal Archives 1860-2000 |
| timestamp | 2024-05-06T09:59:19.196Z |
| titel | Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer |
| titel_suche | Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer |
| topic | WW-YZ |
| uid | nat_lic_papers_NLM196736021 |